DYN:NYE-Dynegy Inc. (USD)

EQUITY | Biotechnology | New York Stock Exchange

Last Closing

USD 33.07

Change

0.00 (0.00)%

Market Cap

USD 1.03B

Volume

0.58M

Analyst Target

USD 10.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Dynegy Inc, through its subsidiaries, is engaged in the production and sale of electric energy, capacity and ancillary services in three segments Coal, IPH and Gas. Its sells electric energy from its power generation facilities.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 122.24B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 115.08B
MRNA Moderna Inc

N/A

USD 51.07B
ARGX argenx NV ADR

N/A

USD 23.44B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 20.96B
BNTX BioNTech SE

N/A

USD 20.40B
BGNE BeiGene Ltd

N/A

USD 17.50B
GMAB Genmab AS

N/A

USD 16.65B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 15.98B
RPRX Royalty Pharma Plc

N/A

USD 15.90B

ETFs Containing DYN

BBC Virtus LifeSci Biotech Cl.. 2.34 % 0.79 %

N/A

USD 0.01B
XBI SPDR® S&P Biotech ETF 1.38 % 0.35 %

N/A

USD 7.07B
CURE:AU ETFS S&P Biotech ETF 1.29 % 0.00 %

N/A

USD 0.04B
IWC iShares Micro-Cap ETF 0.58 % 0.60 %

N/A

USD 0.82B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

N/A

USD 1.01B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 148.65% 95% A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 148.65% 95% A 97% N/A
Trailing 12 Months  
Capital Gain 202.01% 97% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 202.01% 97% N/A 98% N/A
Trailing 5 Years  
Capital Gain 158.16% 87% B+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 158.16% 87% B+ 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 702.69% 97% N/A 98% N/A
Dividend Return 705.05% 97% N/A 98% N/A
Total Return 2.36% 50% F 56% F
Risk Return Profile  
Volatility (Standard Deviation) 1,696.97% 5% F 2% F
Risk Adjusted Return 41.55% 89% A- 73% C
Market Capitalization 1.03B 93% A 85% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 4.27 55% 86%
Price/Book Ratio 24.40 6% 4%
Price / Cash Flow Ratio -17.18 89% 87%
Price/Free Cash Flow Ratio -8.87 85% 83%
Management Effectiveness  
Return on Equity -71.50% 51% 26%
Return on Invested Capital -140.93% 20% 8%
Return on Assets -40.98% 35% 12%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector